The Burnham Center for Chemical Genomics, with a strong track record in the MLSCN phase and impressive institutional support, is poised to contribute to the Molecular Libraries Probe Production Centers Network (MLPCN) as a Comprehensive Screening Center. The Burnham Center is probably the most diverse of all Network Centers, offering not only basic HTS and uHTS capabilities and outstanding medicinal chemistry, but also (i) advanced development of phenotypic screens based on multi-spectral high throughput microscopy (HTM);(ii) microfluidics technology for rapid multi-parallel synthesis of compound analogues;(iii) strong capabilities in NMR-based compound optimization using fragment-based approaches;(iv) advanced 3D computational modeling and structure-based compound optimization capabilities;and (v) exploratory pharmacology. In preparation for the MLPCN Phase, additional institutional support was provided for expanding the capabilities of the Center, including an additional uHTS system. Altogether, the Burnham Center stands ready to advance the mission of the NIH Roadmap into full Production Phase. The Burnham Center is organized into 5 Units that support the User-driven goals of MLPCN, and 2 Center-driven projects aimed at advancing the field of chemical genomics in an integrated manner. Supporting MLPCN's core mission are the following Units: (1) Assay development, adaptation and implementation, which includes world-class expertise in high-content (HC) assay and software development;(2) HTS, ready to handle now the throughput and diversity of HTS demands of MLPCN, with capacity to expand for meeting any future throughput demands;(3) Chemistry, which includes integrated subunits devoted to (a) medicinal chemistry, (b) cheminformatics, (c) NMR-based technologies for compound validation and optimization, and (d) exploratory pharmacology;(4) Informatics, with a powerful supporting relational database with links to >8 million commercially available compounds and multi-Terabyte archiving capacity for supporting HC applications;and (5) Administration. The infrastructure for accomplishing these goals was established during the MLSCN phase, including all aspects of data and resource sharing;collaborative interactions with assay providers, other Network Centers and NIH;inter-institutional IP management;and internal Center governance, thus positioning our Center to deliver results immediately. The Center-driven projects focus on: (1) applications of continuous-flow microreactor technology for addressing the medicinal chemistry bottleneck, reducing the time and costs of compound analoging to a fraction of current standards;and (2) development of advanced SD-imaging technologies for HC screening (HCS), including (a) 3D cell culture systems;(b) innovative HTM instrumentation;and (c) novel imaging algorithms and software, which will enable a new generation of chemical genomics applications that push technology applications beyond monolaver cell cultures.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HG005033-05
Application #
8336979
Study Section
Special Emphasis Panel (ZRG1-IFCN-K (52))
Program Officer
Ozenberger, Bradley
Project Start
2008-09-01
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2014-05-31
Support Year
5
Fiscal Year
2012
Total Cost
$7,500,000
Indirect Cost
$4,684,566
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Ardecky, Robert J; Bobkova, Ekaterina V; Kiffer-Moreira, Tina et al. (2014) Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes. Bioorg Med Chem Lett 24:1000-4
Sugarman, Eliot; Koo, Ada; Suyama, Eigo et al. (2014) Identification of Inhibitors of triacylglyceride accumulation in muscle cells: comparing HTS results from 1536-well plate-based and high-content platforms. J Biomol Screen 19:77-87
Chung, Thomas D Y (2014) Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models. Comb Chem High Throughput Screen 17:272-89
Jiang, Jian-kang; McCoy, Joshua G; Shen, Min et al. (2014) A novel class of ion displacement ligands as antagonists of the ?IIb?3 receptor that limit conformational reorganization of the receptor. Bioorg Med Chem Lett 24:1148-53
Stanford, Stephanie M; Krishnamurthy, Divya; Kulkarni, Rhushikesh A et al. (2014) pCAP-based peptide substrates: the new tool in the box of tyrosine phosphatase assays. Methods 65:165-74
Hershberger, Paul M; Hedrick, Michael P; Peddibhotla, Satyamaheshwar et al. (2014) Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg Med Chem Lett 24:262-7
Ahmed, Vanessa F; Bottini, Nunzio; Barrios, Amy M (2014) Covalent inhibition of the lymphoid tyrosine phosphatase. ChemMedChem 9:296-9
Bravo, Yalda; Teriete, Peter; Dhanya, Raveendra-Panickar et al. (2014) Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. Bioorg Med Chem Lett 24:4308-11
Ardecky, Robert J; Welsh, Kate; Finlay, Darren et al. (2013) Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP. Bioorg Med Chem Lett 23:4253-7
Bobkova, Ekaterina V; Kiffer-Moreira, Tina; Sergienko, Eduard A (2013) Modulators of intestinal alkaline phosphatase. Methods Mol Biol 1053:135-44

Showing the most recent 10 out of 36 publications